文献库搜索 | GeneLibs

Canson(DM),Parsons(MT),Moir-Meyer(G),Dumen... Genome Res 2025-09-02

BRCA1 and BRCA2 germline variant classification is vital for clinical management of families with hereditary breast and ...

Vlaming(M),Koole(W),van Moorselaar(RJA),Bl... BJU Int 2025-12-00

...BRCA2, ATM, CHEK2 and PALB2 was offered to patients with mPCa. We assessed the prevalence of gPVs and compared it to a r...

Harary(PM),Hori(YS),Kattaa(AH),Lam(FC),Abu... J Clin Neurosci 2025-11-00

...BRCA2 (p.K3326*). Our case series indicates that SRS may be an effective management option for erCCC BM, demonstrating h...

Mahiou(K),Bonneau(C),Coutant(C),Martin(AL)... Clin Breast Cancer 2025-12-00

...BRCA2) by age 80. Surgical management in this population is crucial, as it directly impacts quality of life (QoL). Howev...

Abdelmaksoud-Dammak(R),Ammous-Boukhris(N),... Front Oncol None

...BRCA2 variant (c.1813delA, p.Ile605TyrTer9), which provides a potential target for personalized therapy. This case repor...

Kong(M),Jia(J),Liu(C),Liu(H),Zhang(S) Front Med (Lausanne) None

...BRCA2, BUB1B, HSP90AA1, PLK4, and EDIL3), with EDIL3 showing the greatest increase in BA. EDIL3 is located on chromosome...

Abdel-Razeq(H),Tamimi(F),Abdel-Razeq(S),Sh... Oncol Rev None

...BRCA2, represents a critical tool for precision oncology, enabling individualized risk stratification and the developmen...

Ciniselli(CM),Conca(E),Bartoletti(M),Colom... JCO Precis Oncol 2025-09-00

...BRCA2 (6.5%) variants, CGP revealed further potentially actionable alterations (amplifications and/or mutations) in CCNE...

Yan(B),Gao(Y),Zou(Y),Zhao(L),Li(Z) Cancer Biother Radiopharm 2025-08-29

...BRCA2], ataxia-telangiectasia mutated [ATM]), androgen receptor (AR) signaling regulators, and metabolic enzymes (ATP ci...

Nandakumar(S),Mehine(M),Kemel(Y),Bandlamud... Acta Neuropathol 2025-09-12

...BRCA2 (n = 11; 0.5%), TP53 (n = 8; 0.4%), NF1 (n = 8; 0.4%), CHEK2 (n = 21, 0.9% excluding common variant I157T), and th...